Loading data for LBRX — first visit, this takes a few seconds.
LB Pharmaceuticals Inc (LBRX)
NasdaqGM: LBRX
· Real-Time Price · USD
48.94
+0.17 (0.35%)
At close: Aug 19, 2026, 3:59 PM
48.94
+0.00%
After-hours: 7:30 PM
LB Pharmaceuticals Inc (LBRX) Stock Price, Analysis & Data
0.35% (1D)
| Bid | n/a |
| Market Cap | 1.58B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85.69M |
| Beta | n/a |
| EPS (ttm) | -5.1 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.89 |
| P/B (ttm) | 4.22 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | n/a |
| Volume | 161,471 |
| Avg. Volume (20D) | 320,365 |
| Open | 49.80 |
| Previous Close | 48.77 |
| Day's Range | 48.23 - 49.97 |
| 52-Week Range | 13.36 - 49.97 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 11, 2025
Employees 49
Stock Exchange NasdaqGM
Ticker Symbol LBRX
Website https://lbpharma.us
Financial Performance
In 2025, LB Pharmaceuticals Inc's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -25.2M, a decrease of -60.06%.
Financial StatementsEarnings Surprise
LB Pharmaceuticals Inc has released their quarterly earnings on Aug 11, 2026:
LB Pharmaceuticals Inc is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2